GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.
MAIA Biotechnology Capex-to-Revenue Historical Data
The historical data trend for MAIA Biotechnology's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MAIA Biotechnology's Capex-to-Revenue
For the Biotechnology subindustry, MAIA Biotechnology's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MAIA Biotechnology's Capex-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MAIA Biotechnology's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where MAIA Biotechnology's Capex-to-Revenue falls into.
MAIA Biotechnology Capex-to-Revenue Calculation
MAIA Biotechnology's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
MAIA Biotechnology Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of MAIA Biotechnology's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
MAIA Biotechnology (MAIA Biotechnology) Business Description
MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MAIA has been successfully added to your 